GLYC

GlycoMimetics Inc

Last Updated:

Q3'20

Price

quotes and stock data delayed 15 minutes

Cash

$142.9M

Burn Rate (Qtr)

$13.7M

Company Profile

GlycoMimetics is an oncology-focused biotechnology company. We are dedicated to improving the lives of patients by discovering, developing and commercializing novel, small-molecule glycomimetic product candidates.

Drug Pipeline

Click on drug name or indication to see upcoming trial info, prior data, and more general information

Drug | Disease (links)

Stage (next event)

Catalyst Date

Rivipansel (GMI-1070)

SCD - Acute Vaso-Occlusive Crisis (VOC)

Phase 3

December 7, 2020

Uproleselan/GMI-1687

Relapsed/Refractory AML

Phase 3

2H 2021

Uproleselan/GMI-1687

Newly-Diagnosed AML patients Fit for Chemotherapy

Phase 3

TBD

Recent Posts

See what the community is saying - click to see full post

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon